Amgen - In Brief This Week: Janssen, Amgen, Daiichi Sankyo, AstraZeneca, Interpace Biosciences

Amgen – In Brief This Week: Janssen, Amgen, Daiichi Sankyo, AstraZeneca, Interpace Biosciences

Amgen reported detailed results this week from the Phase II CodeBreak-100 trial, in which the company is investigating the activity of sotorasib in …

Amgen – In Brief This Week: Janssen, Amgen, Daiichi Sankyo, AstraZeneca, Interpace Biosciences

Apple Wants More Macs in Businesses: Can It Take on Intel vPro, AMD Ryzen Pro?

Fed’s Kaplan Expects ‘Enthusiastic’ Debate on Taper Timing

Judie Simms

Related Posts

Amgen – Amgen Inc. stock outperforms competitors despite losses on the day

Amgen – Hepatocellular Carcinoma HCC Treatment Market In-Depth Analysis on Size, Cost Structure and Prominent Key Players- Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.

Amgen – Ear Cancer Treatment Market Insights, Trends, Size, Share and Forecast 2020 – 2027 | Key Players – Merck, GSK, Amgen. – KSU

Amgen – Janux raises $56M to take safer T-cell engagers into the clinic

Amgen – Covid-19 impact on Optic Neuropathy Drug Market Key Vendors, Regional Analysis and Competitive Landscape Forecast by 2026| Amgen Inc, BioAxone BioSciences Inc, Ironwood Pharmaceuticals Inc, Quark Pharmaceuticals Inc, Regenera Pharma Ltd, Regeneron Pharmaceuticals Inc – KSU

Amgen – Immuno-oncology Therapy Market In Depth Research by Industry Size, Share, Key Players, Trends and Forecast by 2026 | Amgen, AstraZeneca, Bristol-Myers Squibb, Eli-Lilly, Roche – KSU

Amgen – Global Leiomyosarcoma Treatment Market Is Growing At A CAGR Of 4.30% 2021-2028 | Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Genentech Inc., F. Hoffmann-La Roche AG, Amgen Inc., AstraZeneca, Daiichi Sankyo Company Limited, AB Sciences, AgonOX

Amgen – Erythropoietin Drugs Market Analysis with Trends and Opportunities

Amgen – Cell and Gene Therapy Market – Amgen, Biogen, BioMarin

Fed’s Kaplan Expects ‘Enthusiastic’ Debate on Taper Timing

Facebook - Facebook seeks a new head of U.S. public policy

Here's Why I Think Griffon (NYSE:GFF) Might Deserve Your Attention Today

Leave a Reply Cancel reply